Ophirex, Inc. is a Public-benefit corporation committed to developing the world's first small molecule therapeutics for snakebite and raising awareness about snakebite, a most-neglected epidemic. The plight of snakebite victims and their families is the focus of our commitment.

Ongoing research studies in collaboration with the California Academy of Sciences, University of California, San Francisco as well as international partners are focused on:

  • Understanding local climates and the related impact on snakebite incidence throughout the world
  • Widespread disparities in the reporting and treatment of snakebite between male and female victims of snakebite
  • The economics of snakebite treatment in developing countries
  • The fundamental mechanisms by which our lead compounds achieve their effect taps into fundamental biological pathways whose better understanding will lead to further improvements in the treatment of snakebite and other envenomations